12 completed, 4 recruiting, 3 terminated, 2 approved for marketing. 10 Phase 3, 4 Phase 2, 4 Phase 4, 2 Phase 1, 1 Not applicable.
Follow Fenfluramine: new trials by email Literature Review of Fenfluramine trials Research Report on Fenfluramine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome fenfluramine hydrochloride, Placebo - Rett Syndrome | Phase 3 | Recruiting | UCB BIOSCIENCES, Inc. | 200 | 2026-07-14 | 2026-11-02 |
| Using Fenfluramine to Test the Serotonin Deficiency Theory of Depression Fenfluramine Hydrochloride, [11C]Cimbi-36, Placebo - Depression - Major Depressive Disorder | Not applicable | Not yet recruiting | Imperial College Healthcare NHS Trust | 46 | 2026-07-01 | 2026-06-16 |
| EEG Dynamics in Lennox-Gastaut Syndrome Patients Undergoing Fenfluramine Treatment fenfluramine HCl - Lennox Gastaut Syndrome (LGS) | Enrolling by invitation | University of Chicago | 20 | 2026-05-01 | 2026-08-06 | |
| The FINTEPLA as an Anti-SUDEP Therapy in Dravet Syndrome Project Fenfluramine treatment (Fintepla), Hypercapnia Challenge using the device (RespirAct) - Dravet Syndrome | Phase 4 | Recruiting | The University of Texas Health Science Center, Houston | 25 | 2026-04-27 | 2026-07-15 |
| A Study to Assess Drug-drug Interaction of ZX008 in Healthy Male and Female Study Participants midazolam, metformin, bupropion - Healthy Study Participants | Phase 1 | Completed | UCB BIOSCIENCES, Inc. | 22 | 2024-12-04 | 2026-07-02 |
| Assessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under 24 Months of Age fenfluramine - Dravet Syndrome (DS), Children Under 2 Years | Phase 4 | Recruiting | University of Colorado, Denver | 5 | 2024-10-22 | 2026-05-15 |
| A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome fenfluramine - Dravet Syndrome | Phase 3 | Completed | UCB BIOSCIENCES, Inc. | 25 | 2024-05-21 | 2026-09-17 |
| Treatment of Refractory Infantile Spasms With Fenfluramine Fenfluramine - Infantile Spasm | Phase 2 | Recruiting | Children's Hospital of Orange County | 10 | 2023-06-16 | 2026-04-15 |
| Fenfluramine for Adult Dravet Patients Fenfluramine - Dravet Syndrome, Dravet Syndrome, Intractable | Phase 3 | Terminated | University Health Network, Toronto | 7 | 2023-01-11 | 2026-05-05 |
| Fenfluramine for the Treatment of Different Types of Developmental and Epileptic Encephalopathies: a Pilot Trial Exploring Epileptic and Non-epileptic Outcomes Fenfluramine - Refractory Epilepsy, SYNGAP1 Encephalopathy | Phase 4 | Completed | Hospital Ruber Internacional | 20 | 2022-10-20 | 2026-09-29 |
| A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder. Fenfluramine, Placebo - CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure | Phase 3 | Active not recruiting | Zogenix, Inc. | 87 | 2022-03-08 | 2026-04-29 |
| Fenfluramine and Cognition Fenfluramine, Placebo - Cognitive Function | Phase 4 | Completed | University of Oxford | 56 | 2021-04-12 | 2022-11-15 |
| Fenfluramine in CDKL5 Deficiency Disorder (CDD) Fenfluramine Hydrochloride - CDD | Phase 2 | Completed | NYU Langone Health | 7 | 2019-10-29 | 2023-10-04 |
| Treatment of Sunflower Syndrome With ZX008 (Fenfluramine Hydrochloride) in Children and Young Adults (Ages 4-25). Fenfluramine Hydrochloride - Photosensitive Epilepsy | Phase 3 | Completed | Elizabeth Anne Thiele | 20 | 2019-05-31 | 2024-11-06 |
| A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome ZX008 (Fenfluramine Hydrochloride) - Dravet Syndrome, Lennox Gastaut Syndrome | Phase 3 | Completed | Zogenix, Inc. | 412 | 2019-04-22 | 2025-11-17 |
| A Study to Assess the Usability of the Embrace Seizure Detection Watch in Children and Young Adults With Dravet Syndrome ZX008 (Fenfluramine Hydrochloride) - Dravet Syndrome | Phase 3 | Terminated | Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. | 5 | 2017-07-12 | 2023-11-13 |
| A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome ZX008 (Fenfluramine Hydrochloride), Matching Placebo - Dravet Syndrome | Phase 3 | Completed | Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. | 87 | 2017-01-27 | 2022-11-02 |
| An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome ZX008 (Fenfluramine Hydrochloride) - Dravet Syndrome | Phase 3 | Completed | Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. | 375 | 2016-06-08 | 2025-07-14 |
| A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome ZX008 (Fenfluramine Hydrochloride), Matching Placebo - Dravet Syndrome, Seizure Disorder | Phase 3 | Completed | Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. | 262 | 2016-01-15 | 2023-09-28 |
| Add-on Therapy With Low Dose Fenfluramine in Lennox Gastaut Epilepsy Fenfluramine - Epilepsy, Lennox Gastaut Syndrome | Phase 2 | Completed | KU Leuven | 13 | 2016-01-01 | 2026-10-20 |
Showing 20 of 24. Sign in to see all of them.
Epilepsies, Myoclonic (12) · Epilepsy (8) · Brain Diseases (5) · Seizures (5) · Lennox Gastaut Syndrome (3) · Spasms, Infantile (2) · CDKL5 deficiency disorder (1) · Chromosome 15q, tetrasomy (1) · Cocaine-Related Disorders (1) · Depressive Disorder, Major (1) · Drug Resistant Epilepsy (1) · Epilepsy, Reflex (1) · Epilepsy, Tonic-Clonic (1) · Epileptic Encephalopathy, Early Infantile, 4 (1) · Genetic Diseases, Inborn (1)
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. (4) · UCB BIOSCIENCES, Inc. (3) · Zogenix, Inc. (3) · Children's Hospital of Orange County (1) · Elizabeth Anne Thiele (1) · Hospital Ruber Internacional (1) · Imperial College Healthcare NHS Trust (1) · KU Leuven (1) · NYU Langone Health (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · National Institute on Drug Abuse (NIDA) (1) · The University of Texas Health Science Center, Houston (1) · University Health Network, Toronto (1) · University of California, Los Angeles (1) · University of Chicago (1)
United States (17) · United Kingdom (9) · Belgium (7) · Germany (7) · Spain (7) · Italy (6) · Canada (5) · France (5) · Japan (4) · Netherlands (4) · Australia (3) · Denmark (3) · Georgia (2) · Israel (2) · Poland (2)
Antonio Gil-Nagel, MD, PHD (1) · Catherine J Harmer, DPhil (1) · Daniel Shrey, MD (1) · David Nutt, Professor (1) · Elizabeth Thiele, M.D., Ph.D. (1) · Kelly Knupp, MD (1) · Laure Buydens-Branchey, M.D. (1) · Lieven G Lagae, MD, PhD (1) · Orrin Devinsky, MD (1) · Phillip Cowen, Professor (1) · Samden Lhatoo, MD, FRCP (1)
PMID 34768178, PMID 33540241, PMID 30146701, PMID 31790543, PMID 31862249, PMID 33979451, PMID 34676542, PMID 36562419, PMID 37543865, PMID 39122687, PMID 40072476
2016 (1), 2019 (1), 2023 (1), 2025 (1), R01HL029188 (1)